Cost-Benefit Analysis of Endocrine Therapy in the Adjuvant Setting for Postmenopausal Patients with Hormone Receptor-Positive Breast Cancer, Based on Survival Data and Future Prices for Generic Drugs in the Context of the German Health Care System

Breast care

Michael P. Lux¹  Matthias W. Beckmann¹  Jon Karnon¹  Claudia Reichelt¹  Falk C. Thiel¹  Thorsten D. Tänzer¹  Dragan Radosavac¹  Peter A. Fasching¹ 

[1] aUniversity Breast Center for Franconia, Frauenklinik des Universitätsklinikums Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen

关键词: Letrozole;    Anastrozole;    Tamoxifen;    Cost-effectiveness;    QALY;    BIG 1–98;    ATAC;   

DOI  :  10.1159/000333118

学科分类：泌尿医学

来源: S Karger AG

【 摘 要 】

Cost-effectiveness analyses have focused on aromatase inhibitors (AIs), but the results are inconsistent and disease-free survival has often been extrapolated to overall survival. The present study calculates the cost-effectiveness of 5 years of letrozole versus tamoxifen versus anastrozole in the context of the German health care system, using survival data from the Breast International Group (BIG) 1–98 study and the Arimidex, Tamoxifen, Alone or in Combination (ATAC) study and generic prices.

【 授权许可】

Unknown